Arête Therapeutics has discovered a series of novel and diverse chemical classes of soluble epoxide hydrolase (s-EH) inhibitors and is focused on developing these compounds to become ‘first-in-class’ therapeutics to treat cardiovascular, metabolic and inflammatory diseases.

• AR9281
• Pre-Clinical Development
• Market Opportunities